VRDN - CIK 0001590750
The table below shows Viridian Therapeutics, Inc.DE's balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | - | - | - | - | - | - |
| Short-term investments | - | - | - | - | $154.67M | $81.74M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets | $894.23M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $738.46M |
| $486.48M |
| $431.17M |
| $200.16M |
| $129.61M |
| Property, plant & equipment | $1.23M | $1.24M | $1.67M | $1.33M | $375.00K | $309.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $899.42M | $742.40M | $490.42M | $435.09M | $203.71M | $131.25M |
| Accounts payable | $8.68M | $2.14M | $2.24M | $14.23M | $2.33M | $670.00K |
| Total current liabilities | $70.70M | $47.87M | $26.64M | $33.35M | $13.64M | $10.67M |
| Long-term debt | - | $20.58M | $20.20M | $4.64M | - | - |
| Total liabilities | $177.25M | $70.76M | $48.40M | $40.03M | $15.99M | $11.22M |
| Retained earnings | -$1.34B | -$995.86M | -$725.91M | -$488.17M | -$358.30M | -$278.89M |
| Total equity | $722.17M | $671.64M | $442.02M | $395.06M | $187.72M | $120.04M |